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CYP3A4Abstract Introduction: Drug–drug interactions can lead to serious and potentially lethal adverse
events. In recent years, several drugs have been withdrawn from the market due to interaction-
related adverse events. The objective of this study was to evaluate the pharmacokinetic interaction
between pioglitazone (PG) and carbamazepine (CBZ) in healthy male rabbits.
Methods: A randomized, two-crossover design study was conducted in six healthy male rabbits. The
study consisted of two periods: period one, when each rabbit received a single dose of 70 mg CBZ-sus-
pension. Period two, when each rabbit received a single dose of 70 mg CBZ-suspension co-administered
with a single dose of 1.5 mg PG with a washout period of one week between the two periods. Serial
blood samples were collected over a period of 48 h. Chemiluminescent enzyme immunoassay (CLEIA)
was used to measure CBZ in serum. Pharmacokinetic (PK) parameters Cmax, Tmax, t 1/2, AUC0-t, AUC
0-1, and ke were determined for the two periods using non-compartmental analysis.
Results: In the two periods of treatment, Cmax, Tmax, AUC0-t, AUC0-1, t ½ and ke for CBZ were
administered alone and in combination with PG. Cmax, the mean peak plasma concentration was
4.33 ± 2.4 lg/mL versus 4.76 ± 2.1 lg/ml, tmax, time taken to reach, was 2.91 ± 1.11 h versus
3.6 ± 1.83 h, total area under the curve AUC0-t was 64.90 ± 43.6 lgÆh/ml versus 102.90 ± 66.9 lgÆh/
ml, AUC0-1 was 74.0 ± 52.6 lgÆh/ml versus 124.3 ± 85 lgÆh/mL, t ½ was 14.10 ± 2.5 h versus
16.43 ± 6.43 h and elimination rate constant ke was 0.050 ± 0.009 h
1 versus 0.057 ± 0.049 h1,
respectively. No statistical differences were found in pharmacokinetic of CBZ in both cases (P > 0.05).
Conclusion: The result of the study demonstrated that PG does not affect pharmacokinetic param-
eters of CBZ. Therefore, no cautions regarding dose or administration pattern of CBZ with PG should
be taken.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Interaction between drugs represents a major clinical concern
for health care professionals and their patients. It occurs when
one therapeutic agent either alters the concentrations or the
biological effect of another agent (GhavimI et al., 2013). Many
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tion or inhibition of cytochrome P450 (CYP) enzymes, the
major drug-metabolizing enzymes mainly present in the liver
(Wilkinson, 2005; Sahi et al., 2003). It has been estimated that
70% of human drug oxidation can be attributed to six main
enzymes CYP1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (Tanaka,
1999). Patients affected by both diabetes type 2 DM and
epilepsy can be treated by pioglitazone and carbamazepine at
the same time. Pioglitazone (PG) is a thiazolidinedione
compound used in the treatment of type 2 DM. It is an insulin
sensitizer that acts as an agonist of the peroxisome
proliferator-activated receptor subtype gamma (PPAR-c),
(Yki-Jarvinen, 2004; Lehmann et al., 1995). It is well-absorbed,
with a mean absolute bioavailability of 83% and reaching
maximum concentrations in around 1.5 h (Hanefeld, 2001;
Eckland and Danhof, 2000). Moreover, it is extensively metab-
olized by hydroxylation and oxidation to active and inactive
metabolites in the liver predominantly via cytochrome P450
(CYP) isoenzymes, CYP2C8 and CYP3A4 (Hanefeld, 2001;
Eckland and Danhof, 2000).
Carbamazepine (CBZ) is one of the most commonly pre-
scribed antiepileptic drugs and is also used in the treatment
of trigeminal neuralgia and psychiatric disorders, particularly
bipolar depression (Galal et al., 2004). It has a dissolution
dependent oral bioavailability due to its low solubility in water
(113 lg ml1, 25 C) exhibiting a slow and irregular gastroin-
testinal absorption (Sethia and Squillante, 2004; Barakat and
Radwan, 2006). CBZ is a potent inducer of CYP isoenzymes
CYP1A2, CYP2C9, CYP2C19, and CYP3A4 (Anderson,
1998; Spina et al., 2005). However, it is metabolized by
CYP3A4 to give carbamazepine-10,11-epoxide, the major
active metabolite representing 80% of CBZ in man (Kerr
et al., 1994; Patsalos et al., 2002). So, CBZ shows a relatively
short half-life, in chronic treatment, due to autoinduction of
the drug metabolism (Giunchedi et al., 1991). Furthermore,
its half-life may be shortened by coadministration of other
CYP3A4 inducer drugs (Galal et al., 2004).
PG showed in vitro inductive effects on CYP3A4 (Sahi
et al., 2003). This could inﬂuence pharmacokinetic of CBZ.
Alteration in pharmacokinetics of such antiepileptic may cause
toxicity or loss of seizure control. Therefore, this study was
conducted to assess the possibility of potential interaction of
PG with CBZ.2. Materials and Methods
2.1. Animals
Six healthy male rabbits with mean weight 3.4 ± 0.12 kg,
aged 7–9 months were enrolled in the study. The rabbits
were obtained from Asdda for animal production and wel-
fare center, where follow up care and clinical examination
were performed and rabbits’ health state was certiﬁed
(khanunis, Palestine). Rabbits were fasted for 12 h with free
access to water by ad libitum before the beginning of the
study.
The study was carried out at the Al-Azhar University-
Gaza, College of Pharmacy, Gaza, Palestine. The study was
approved by the institutional ethics committee and was
conducted under supervision of a veterinary physician.2.2. Study design
A single dose, two-crossover design study was conducted in
rabbits. There was a washout period of one week between
the two doses. The rabbits were divided into two groups.
The ﬁrst one received a 70 mg dose of CBZ oral suspension,
whereas the second group received the same dose of CBZ
co-administered with a single dose 1.5 mg of PG as a suspen-
sion prepared in laboratory. PG tablets were pulverized and
a weight of the powder equivalent to 15 mg PG was suspended
in 20 ml distilled water. Carbamazepine suspension (2%,
Tegretol, Novartis) and pioglitazone tablet (30 mg, Actos,
Takeda) were purchased from a local pharmacy (Gaza,
Palestine). After one week the second group received CBZ
alone and the ﬁrst received CBZ concurrently with PG to com-
plete the cross-over design. The dose was given by means of a
syringe connected to an oral gavage. It was put in the corner of
the mouth and the liquid was pushed down slowly, to avoid
choking. General clinical safety was assessed by physical
examination during the study, washout period and at the end
of the study.
2.3. Blood sampling
Rabbits were placed in the rabbit restraining box device. The
marginal ear vein was located and the hair was removed.
Gentle stroking and tapping of the ear may make the vein
more visible. Local anesthetic was applied to prevent the
jerking of the rabbit as a result of venipuncture 15 min before
starting the study by inserting a small needle (23 gauge) butter-
ﬂy attached to a syringe in the marginal ear vein (Parasuraman
et al., 2010). Serial venous blood samples were collected (1 ml)
in vacutainer tubes according to the time schedule 0.0, 0.5, 1.0,
1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 24.0 and 48 h after receiving the
dose. Blood samples were centrifuged at 3,000 rpm for 5 min
and serum was transferred into clean plastic tubes. Serum
samples (ca. 200 ll) were kept in refrigerator until being
analyzed within 24 h.
2.4. Analysis of serum samples
The analysis was performed by the carbamazepine kit based
on chemiluminescent enzyme immunoassay (CLEIA) and
Immulite 1000 immunoassay system (Siemens Healthcare
Diagnostics).
2.5. Pharmacokinetic analysis
The plasma pharmacokinetic parameters were estimated,
which included the observed maximum plasma concentration
Cmax, the time to reach Cmax, (Tmax) and the area under the
plasma concentration–time curve from 0 h to last measurable
concentration (AUC0-t) and 0 h to inﬁnity (AUC0-1). Cmax
and Tmax were directly determined from the serum concentra-
tion versus time curves. The area under the curve from 0 h to t
(AUC0-t) was calculated by the linear trapezoidal rule. The
area under the curve from 0 h to inﬁnity (AUC0-1) was
estimated by summing the area from AUC0-t and AUC0-1,
where AUC0-1=AUC0-t + Ct / ke, with ‘Ct’ deﬁned as the
last measured serum concentration at time t, and ke is the
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estimated by the least squares regression of plasma concentra-
tion–time data points lying in the terminal region by using
semilogarithmic dependence that corresponds to ﬁrst-order
kinetics. The half-life t1/2 was calculated as 0.693/ke. Pharma-
cokinetic analysis was performed by means of model indepen-
dent method (Non-Compartmental Approach) WinNonlin
Professional Software (Version 6.3, Pharsight Corporation,
Cary, NC).
2.6. Statistical analysis
Analysis of Variance (ANOVA) was used to compare the cal-
culated pharmacokinetic parameters of carbamazepine for the
two periods, using general linear model procedures, in which
sources of variation were subject and period. The statistical
analysis was performed using SPSS, version 16. P-value 6 0.05
was considered statistically signiﬁcant.
3. Results
The mean plasma concentrations of carbamazepine when
administered alone or in combination with pioglitazone are
shown in Fig. 1. The concentration time proﬁle obviously indi-
cated that the two periods are comparable. The mean pharma-
cokinetic parameters of carbamazepine administered alone or
in combination with pioglitazone as well as the statistical sig-
niﬁcance following their comparison are given in Table 1.
In the two periods of treatments, Cmax, Tmax, AUC0-t,
AUC0-1, t ½ and ke for CBZ were administered alone and
co-administered with PG. The mean peak plasma concentra-
tion Cmax was 4.33 ± 2.4 lg/mL versus 4.76 ± 2.1 lg/mL,
tmax, time taken to reach Cmax, was 2.91 ± 1.11 h versus
3.6 ± 1.83 h, total area under the curve AUC0-t was
64.90 ± 43.6 lgÆh/mL versus 102.90 ± 66.9 lgÆh/mL,
AUC0-1 was 74.0 ± 52.6 lgÆh/mL versus 124.3 ± 85 lgÆh/mL,
t ½ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate
constant was 0.050 ± 0.009 h1 versus 0.057 ± 0.049 h1,
respectively.Tim
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Figure 1 Mean concentration–time proﬁles of CBZ whStatistically insigniﬁcant differences were found in all phar-
macokinetic parameters of CBZ in both cases (P > 0.05).
4. Discussion
The six healthy male rabbits completed the study without any
deviations. The utility of rabbit as a model to study drug–drug
interactions is well documented (Stargrove et al., 2008; Riviere,
2007). All six rabbits had completed the study and there were
nodeath or replacement during the study.Clinical physical exam-
ination during and post study indicated no abnormalities. The
present study showed good tolerability of both formulations.
As recognized, the primary organ involved in drug metab-
olism is the liver which includes a very important family of
enzymes called cytochrome P450 (CYP). More than 50% of
all drugs are metabolized at least in part by CYP3A4 or
CYP2D6 (Guengerich et al., 1998). As a result, many drug
interactions are a consequence of inhibition or induction of
cytochrome P450 (CYP) enzymes (GhavimI et al., 2013). As
known, carbamazepine is metabolized by CYP3A4 to give
carbamazepine-10,11-epoxide (Kerr et al., 1994), so co admin-
istration of CBZ with CYP3A4 inducers or inhibitors can
affect its plasma concentration (Galal et al., 2004). Previous
studies demonstrated that the mean serum concentration of
carbamazepine was lower when the drug was given in
combination with CYP3A4 inducers such as phenytoin
(59Æ4%), primidone (58Æ2%), phenobarbital (65Æ7%) and val-
proate (83Æ0%) than when carbamazepine was given alone
(100%), (Brodie et al., 1983; Rambeck et al., 1987). PG has
an inductive effect on CYP3A4 activity, which was established
by in vitro testing using primary human hepatocytes (Sahi
et al., 2003). An in vivo study showed similar effects of PG,
where it was found that sub-chronic concurrent administration
of PG (10 mg/kg) with phenytoin (30 mg/kg), antiepileptic
drug metabolized mainly by CYP3A4 (Cuttle et al., 2000;
Komatsu et al., 2000), was associated with signiﬁcant reduc-
tion in its plasma concentration in rats.
Despite in vitro effect of PG on CYP3A4, the pharmacoki-
netics of CBZ was not affected in rabbits. In vitro results aree (h)
25 30 35 40 45 50
 CBZ 
 CBZ with PG
en administered alone and in combination with PG.
Table 1 Summary of mean pharmacokinetic parameters of CBZ 70 mg alone and in combination with 1.5 mg of PG in rabbits
(n = 6).
Pharmacokinetic parametersa CBZb Mean ± SDd CBZ+ PGc Mean ± SDd p-Valuee
Cmax (lg/ml) 4.33 ± 2.41 4.76 ± 2.16 0.697
Tmax (h) 2.91 ± 1.11 3.6 ± 1.83 0.328
AUC 0-48 (lg.h/ml) 64.90 ± 43.6 102.90 ± 66.9 0.328
AUC 0-1 (lg.h/ml) 74.00 ± 52.6 124.30 ± 85 0.726
t½ (h) 14.10 ± 2.5 16.43 ± 6.43 0.269
Ke (h
1) 0.050 ± 0.0090 0.057 ± 0.049 0.245
a Abbreviations are Cmax: Maximum serum concentration, Tmax: Time taken to reach Cmax, AUC0-48: Area under the curve from 0 h to 48 h,
AUC0-1: Area under the curve from 0 h to inﬁnity, t1/2: Terminal half-life and Ke: Terminal elimination constant.
b Rabbits received 70 mg CBZ.
c Rabbits received CBZ in combination with 1.5 mg PG.
d SD: Standard deviation.
e Statistical signiﬁcance p 6 0.05.
180 I. Abushammalanot necessarily extrapolated to in vivo model. St John’s Wort,
in vitro CYP3A4 inducer, did not signiﬁcantly affect the phar-
macokinetic parameters of CBZ (Burstein et al., 2000).
We think that the suitable interpretation of our results that
pioglitazone has the potential to cause drug–drug interactions
through induction of CYP3A4 if sufﬁcient concentration
(50 lM) is achieved in the liver.
5. Conclusions
It has been found that PG does not affect the pharmacokinet-
ics of CBZ.
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